Fig. 9From: Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trialsAflibercept versus ranibizumab. Mean change in central macular thickness (μm) from baseline comparing aflibercept with ranibizumab at 1. IV, inverse variance; SD, standard deviationBack to article page